Overview

Gender

male

Yanfeng Wang, Ph.D. has over 20 years of industry experience in both large Pharma (Novartis and Merck) and Biotech (Ionis) companies, including 7 years in Nonclinical Tox/DMPK and 14 years in PK/Clinical Pharmacology. Yanfeng has spent much of his career supporting Oncology drug development. He has contributed to multiple NDA submissions including Tasigna, Signifor; Odomzo, Zykadia, and Midostaurin, as well as sNDA submissions for Glivec, Sandostatin LAR, Ritalin LAR and Focalin LAR new formulation development all at Novartis. Currently Yanfeng is an Executive Director of the PK and Clinical Pharmacology department at Ionis, a leading biopharmaceutical company specialized in antisense oligonucleotides drug development. At Ionis, he has the opportunity to support another NDA submission for Nusinersen, a novel and first-in-class therapy for paediatric patients with spinal muscular atrophy. Dr. Wang has published over 70 papers in refereed journals. He earned his Ph.D. in pharmaceutical sciences at the University of Minnesota under the direction of Professor Ronald Sawchuk. He is a member of AAPS, ASCPT, ASCO, ISSX, SAPA.